- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MedAlliance to shed remaining assets
Former imaging services firmMedAlliance of Brentwood, TN, is close to completing its planfor self-liquidation. The company announced last month that itwill sell its physician ancillary site business to National MedicalCare for $16.2 million plus the
Former imaging services firmMedAlliance of Brentwood, TN, is close to completing its planfor self-liquidation. The company announced last month that itwill sell its physician ancillary site business to National MedicalCare for $16.2 million plus the assumption of liabilities.
The physician ancillary site business provides the equipment,technologists and billing for medical imaging services at over200 sites, primarily in the Northeast.
MedAlliance, formerly known as ImageAmerica, recently completedthe sale of 15 imaging centers to Health Images of Atlanta (SCAN4/16/94 and 1/18/95). Earlier last month, MedAlliance agreed tosell its 70% interest in a partnership that owns a Little Rock,AR, imaging center for $12.5 million.
The sales complete the disposition of all the operating assetsof MedAlliance, according to the company. A special shareholdersmeeting has been scheduled to approve a proposal to distributeproceeds from the three sales and for winding up the company'sbusiness.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
